CLINICAL_TRIALS
trial_result
· 2024-01-05
Clinical Trial Update: Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) [Phase 3]
Summary
Phase 3 trial results for AVXS-101 (OAV101) intravenous gene therapy in pediatric spinal muscular atrophy, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Spinal Muscular Atrophy | Phase 3 | Status: COMPLETED | Results posted: 2024-01-05